(C) ChIP assay shows that binding of Smad3 to P2Y12 promoter region is greatly enhanced in BMDMs in response to TGF-β1 (5 ng/mL). (D and E) Flow cytometry shows that the percentage of CD68+P2Y12+ cells is significantly increased in day 7 UUO kidney in Smad3 WT but not in Smad...
Inhibition of the P2Y12 receptor is a well-established strategy for anti-thrombotic therapy; Plavix®(clopidogrel), an irreversible P2Y12 receptor antagonist, is the number one selling drug on the market for antiplatelet therapy [170]. However, P2Y1 is a relatively new target being explored ...